Search results
Showing 46 to 60 of 85 results for lower urinary tract symptoms
Sacral nerve stimulation for urge incontinence and urgency-frequency (HTG37)
Evidence-based recommendations on sacral nerve stimulation for urge incontinence and urgency-frequency. This involves placing electrodes and connecting them to an implantable pulse generator.
View recommendations for HTG37Show all sections
Sections for HTG37
Evidence-based recommendations on retrograde uretral sphincterometry. This involves passing fluid through a small, cone-shaped device placed into the urethra to display the pressure needed to open the urethra sphincter.
View recommendations for HTG109Show all sections
Sections for HTG109
Lower urinary tract symptoms secondary to benign prostatic hyperplasia: tadalafil (ESNM18)
This evidence summary has been updated and replaced by NICE guideline CG97.
This quality standard covers diagnosing and managing urinary tract infection in infants, children and young people (under 16). It includes new and recurrent infections of the upper or lower urinary tract. It describes high-quality care in priority areas for improvement.
View quality statements for QS36Show all sections
Sections for QS36
- Quality statements
- Quality statement 1: Presentation with unexplained fever of 38°C or higher
- Quality statement 2: History and examination – recording of risk factors
- Quality statement 3: Laboratory reporting – differentiation of E. coli and non-E. coli organisms
- Quality statement 4: Information about recognising re-infection
- Update information
- About this quality standard
NICE has developed a medtech innovation briefing (MIB) on Stockholm3 for prostate cancer screening .
UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MTG58)
We have moved Medical technologies guidance 58 to become HealthTech guidance 578. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (MTG26)
This guidance has been updated and replaced by NICE healthtech guidance 578.
This guideline sets out an antimicrobial prescribing strategy for acute sore throat. It aims to limit antibiotic use and reduce antimicrobial resistance. Acute sore throat is often caused by a virus, lasts for about a week, and most people get better without antibiotics. Withholding antibiotics rarely leads to complications.
Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (MTG49)
We have moved Medical technologies guidance 49 to become HealthTech guidance 545. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
NICE has developed a medtech innovation briefing (MIB) on TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation .
Urethrotech UCD for difficult or failed catheterisation (MIB116)
NICE has developed a medtech innovation briefing (MIB) on the Urethrotech UCD for difficult or failed catheterisation .
We have moved interventional procedures guidance 798 to become HealthTech guidance 737. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved interventional procedures guidance 611 to become HealthTech guidance 469. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
QuickChange Incontinence Wrap for urinary incontinence in men (MIB237)
NICE has developed a medtech innovation briefing (MIB) on QuickChange Incontinence Wrap for urinary incontinence in men .
Evidence-based recommendations on botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention. This involves injecting botulinum toxin type A into the urethral sphincter.
View recommendations for HTG685Show all sections